Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotactic factor inactivator in normal human serum.

J L Berenberg, P A Ward

    The Journal of Clinical Investigation
    |May 1, 1973
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    'Biological signals' to 'biological signals and receptors'.

    Biological signals and receptors·1998
    Same author

    In vivo recruitment of neutrophils: consistent requirements for L-arginine and variable requirements for complement and adhesion molecules.

    Inflammation·1998
    Same author

    NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement.

    The American journal of pathology·1998
    Same author

    Streptococcal cell wall-induced arthritis: requirements for IL-4, IL-10, IFN-gamma, and monocyte chemoattractant protein-1.

    Journal of immunology (Baltimore, Md. : 1950)·1998
    Same author

    Lung inflammation and fibrosis.

    American journal of respiratory and critical care medicine·1998
    Same author

    Requirements for alpha d in IgG immune complex-induced rat lung injury.

    Journal of immunology (Baltimore, Md. : 1950)·1998
    Same journal

    Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults.

    The Journal of clinical investigation·2026
    Same journal

    Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

    The Journal of clinical investigation·2026
    Same journal

    Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

    The Journal of clinical investigation·2026
    Same journal

    Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

    The Journal of clinical investigation·2026
    Same journal

    Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

    The Journal of clinical investigation·2026
    Same journal

    SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

    The Journal of clinical investigation·2026
    See all related articles

    Normal human serum contains a chemotactic factor inactivator (CF-I) that broadly neutralizes leukocyte-attracting factors. This inactivator may play a role in regulating inflammatory responses.

    Area of Science:

    • Immunology
    • Biochemistry

    Background:

    • Normal human serum possesses a factor that inactivates chemotactic agents.
    • Chemotactic factors attract neutrophils, crucial for inflammatory and immune responses.

    Purpose of the Study:

    • To characterize the properties and activity spectrum of the chemotactic factor inactivator (CF-I) in normal human serum.
    • To investigate the mechanism of inactivation and its relationship to other serum factors.

    Main Methods:

    • Serum fractionation using ammonium sulfate precipitation.
    • Analysis of CF-I activity against various chemotactic factors, including complement fragments (C3, C5) and bacterial factors.
    • Biophysical characterization using sucrose density ultracentrifugation, electrophoresis, and gel filtration.
    • Radioligand binding studies with C5 chemotactic fragments.

    Related Experiment Videos

    Main Results:

    • CF-I is a soluble factor that directly and irreversibly inactivates a broad range of chemotactic factors.
    • Its activity includes inactivation of C3 and C5 chemotactic fragments, C567, and bacterial chemotactic factors.
    • CF-I exhibits biphasic activity upon ultracentrifugation, electrophoresis, and gel filtration.
    • Inactivation does not appear to result from irreversible binding to the C5 chemotactic fragment.
    • CF-I differs from anaphylatoxin inactivator, but their relationship remains unclear.

    Conclusions:

    • CF-I is a distinct serum component with broad-spectrum inactivation of chemotactic factors.
    • Its mechanism of action is not based on irreversible binding.
    • CF-I likely functions as a key regulator of inflammatory processes by controlling chemotactic signals.